Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases

The main questions it aims to answer are: * If EVM18001 is safe and tolerate in patients with active refractory autoimmune diseases (SLE, MG, and SSc)? * What the recommended dose for subsequent treatment? * What the PK/PD profiles of EVM18001 in patients with active refractory autoimmune diseases (SLE, MG, and SSc)? * What the efficacy of EVM18001 in patients with active refractory autoimmune diseases (SLE, MG, and SSc)# * What the biomarkers and immunogenicity of EVM18001 in treating of patients with active refractory autoimmune diseases (SLE, MG, and SSc)? Participants will: * Inform the investigator in a timely manner when unable to attend a visit. * Report any changes in their health condition to the study doctor, including discomfort or other health issues during the screening period. * Inform the study doctor of any other medications taken before and during the study; inform the study doctor before starting any new medications. * Be informed of any medications which may be affected by the study drug that should not be used during the study. * Agree to use effective contraception during the study and for 12 months after the last infusion of EVM18001EVM injection.